Torrent Pharmaceuticals: FY26 Performance Bolstered by JB Pharma Acquisition

Torrent Pharmaceuticals Limited (TPL) has announced its Integrated Annual Report for FY 2025-26, showcasing a significant 21% surge in consolidated revenue to ₹13,980 crore. This growth was primarily fueled by the strategic acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) in January 2026.

Consolidated operating EBITDA for the fiscal year reached ₹4,559 crore, marking a 22.5% increase. Net profit saw an 11.9% rise, settling at ₹2,138 crore, with Earnings Per Share (EPS) growing 13.2% to ₹63.92.

Reader Takeaway: Strong revenue growth driven by acquisition; leverage increase needs monitoring.

What just happened

Torrent Pharmaceuticals released its FY 2025-26 integrated annual report, detailing robust financial performance. Key highlights include consolidated revenue of ₹13,980 crore, a 21% increase year-on-year, and consolidated operating EBITDA of ₹4,559 crore, up 22.5%. Net profit grew by 11.9% to ₹2,138 crore. A significant event during the year was the acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) in January 2026, with plans for its amalgamation with Torrent Pharma approved by the board.

Why this matters

The acquisition of JB Pharma is a pivotal strategic move, aimed at scaling up Torrent Pharma's operations in India, diversifying its therapeutic offerings, and strengthening its presence in chronic therapies. This integration is expected to elevate Torrent Pharma's ranking to the 5th largest in the Indian Pharmaceutical Market (IPM). The company also raised substantial funds, ₹2,400 crore via Commercial Papers and ₹10,990 crore via Non-Convertible Debentures (NCDs), to finance the acquisition and expansion.

The backstory

India has consistently been Torrent Pharma's largest market, accounting for 54% of its total revenue in FY26. The integration with JB Pharma builds upon this strength. The company has a history of strategic acquisitions to drive growth and market share expansion in key geographies.

What changes now

The amalgamation of JB Pharma with Torrent Pharmaceuticals is expected to create significant operational synergies and market presence. Shareholders can anticipate a more consolidated and stronger entity in the Indian pharmaceutical landscape. The company has also proposed a final dividend of ₹9 per share.

Risks to watch

While the acquisition brings strategic benefits, it has led to an increase in debt levels. The Net Debt/EBITDA ratio rose to 2.3x in FY26 from 0.6x in FY25, primarily due to acquisition financing. Management is confident in deleveraging through strong cash flows. Additionally, the company faces ongoing market pressures such as pricing challenges and intense competition, particularly in the US and German markets. Supply chain disruptions at third-party suppliers have also impacted the German business, causing a 3% revenue degrowth in Euro terms.

Peer comparison

Torrent Pharma's acquisition of JB Pharma places it among the top 5 players in the Indian pharmaceutical market. Competitors in this segment include Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Lupin, all of whom are also focused on expanding their domestic and international footprints through organic growth and strategic M&A.

Context metrics (time-bound)

• Revenue Growth (FY26 vs FY25): 21% increase from ₹11,516 crore to ₹13,980 crore.
• Operating EBITDA Growth (FY26 vs FY25): 22.5% increase from ₹3,721 crore to ₹4,559 crore.
• Net Profit Growth (FY26 vs FY25): 11.9% increase from ₹1,911 crore to ₹2,138 crore.
• Net Debt/EBITDA Ratio: Increased to 2.3x in FY26 from 0.6x in FY25.
• Fundraising in FY26: ₹2,400 crore (CP) + ₹10,990 crore (NCDs).

What to track next

Investors will be closely watching the successful execution of the JB Pharma amalgamation, the realization of expected synergies, and the company's progress in deleveraging its balance sheet. Performance in key markets like India and the US, along with management's ability to navigate pricing pressures and supply chain issues, will be crucial indicators.